Highest-materiality recent filing
Q1 2026 net revenues $5.1M vs $3.2M YoY; operating loss narrowed to $0.3M from $1.5M.
FOXO licenses epigenetics IP to founder's entity; 3% royalty capped at $1.3M, 40% equity option
Exclusive worldwide license of two U.S. patents, 13,000+ dataset, and ML models to LongevityFP Technologies, controlled by founder Jon R. Sabes.
FOXO settles Darbie obligations; shareholder approves 1:1,000–1:10,000 reverse split
Issued 400 Series D Preferred shares to J.H. Darbie; pays $175,000 in 7 monthly installments to resolve all amounts owed.
FOXO Technologies increases authorized shares to 25.02B, effective May 3, 2026
Authorized shares raised to 25.02B: 25B Class A common ($0.0001 par) and 20M preferred ($0.0001 par).
Sylwia Nowak Hauman resigned as CFO on March 18, 2026; resignation letter cited concerns over internal controls, financial reporting, and team resourcing.
FOXO settles $200K debt by issuing 8,000 Series E Preferred shares to Rennova in related-party deal
Issued 8,000 Series E Preferred shares at $25 stated value to Rennova in full satisfaction of $200,000 in Prior Advances.
FOXO Tech increases authorized common shares from 2.5B to 10B; hospital adds tele-specialty
Authorized shares of common stock increased to 10B from 2.5B, effective Jan 18, 2026.
Filed amendments to Series B and C Preferred Stock, revising conversion price to higher of $0.0001 or 90% of 5-day VWAP and removing mandatory conversion.
FOXO CEO year-end review: revenue >$15M expected, Myrtle occupancy 93%, debt reduced
Myrtle Recovery Centers avg daily census 28 (93% occupancy) vs 7.4 (25%) in 2024; projected 550 admissions vs 195.
FOXO Technologies increases authorized common shares from 500M to 2.5B
Authorized common shares increased from 500,000,000 to 2,500,000,000 effective Oct 22, 2025.
FOXO appoints Sylwia Nowak Hauman as CFO, amends Series A Preferred terms
Sylwia Nowak Hauman appointed CFO (Principal Financial & Accounting Officer) effective September 23, 2025.
FOXO closes acquisition of Vector Bio Source; $500K cash, preferred stock, and warrants
On Sept 19, 2025, FOXO completed the purchase of Vector Bio Source, which became a wholly owned subsidiary.
Majority stockholder approves reverse stock split of FOXO common stock at ratio up to 1:500
Rennova Health (controlled by CEO) holds 60% voting rights, approved reverse split via written consent on Sept 2, 2025.
FOXO delisted from NYSE American; board restates Q1 2025 financials for $5.1M error
NYSE American commenced delisting on Aug 12, 2025 due to stock price below $0.10; trading suspended immediately.
FOXO Technologies receives NYSE American delisting notice, moves to OTC market
NYSE Regulation commenced delisting proceedings on Aug 12, 2025 due to low selling price below $0.10.
Facility has 87 units licensed for assisted living and memory care services.
FOXO Tech board approves spin-off of epigenetics subsidiary FOXO Labs
Board approved pursuing spin-off of FOXO Labs, Inc., its epigenetics subsidiary; FOXO shareholders to directly own shares in the new entity.
FOXO Technologies majority stockholder approves 1:1.99 reverse split and multiple share issuances
Majority stockholder (82.08% voting rights) approved reverse stock split at 1:1.99 ratio, effective by Nov 6, 2025.
Formed FOXO Acquisition Corp., a wholly-owned subsidiary for healthcare services acquisitions; plans to create publicly listed non-convertible preferred stock for funding.
Issuance of up to 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock at three closings of 550 shares each.
FOXO files 10-K with going concern opinion; CEO cites transition year and acquisitions
Annual Report on Form 10-K filed on April 15, 2025 for fiscal year ended December 31, 2024.
FOXO Technologies announces 1-for-10 reverse stock split effective April 28, 2025
Reverse stock split at ratio 1:10, effective 4:01pm ET on April 28, 2025.
FOXO executes non-binding agreement to acquire two Florida assisted living facilities for $60M
Total consideration $60M ($30M per facility), with a portion milestone-based.
FOXO CEO reports change of control, debt restructuring, and plans for revenue growth
Shareholders meeting Jan 17, 2025 concluded 2024 acquisition agreements, resulting in change of control of company.
Aggregate principal of $3,457,500 of 15% Senior PIK Notes cancelled and exchanged for 3,457.5 shares of Series B Preferred Stock.
On June 9, 2025, Martin Ward, the Company’s Interim Chief Financial Officer passed away unexpectedly.
On June 13, 2025, the Board of Directors of the Company (with Mr. Lagan abstaining) appointed Seamus Lagan to serve as the Company’s Interim Chief Financial Officer.
the board of directors (the “ Board ”) of the Company appointed Seamus Lagan and Trevor Langley to the Board to serve as directors of the Company, effective September 10, 2024.
the board of directors (the “ Board ”) of the Company appointed Seamus Lagan and Trevor Langley to the Board to serve as directors of the Company, effective September 10, 2024.
appointed Francis Colt deWolf III to the Board to serve as a director of the Company, effective immediately.
Effective November 21, 2023, the Company accepted the resignation of Andrew Poole from the Board of Directors of the Company.
On September 13, 2023, Tyler Danielson notified the Company of his decision to resign as Interim Chief Executive Officer and Chief Technology Officer of the Company, effective as of September 14, 2023.
appointed Mark White to serve as Interim Chief Executive Officer of the Company, effective as of Mr. White’s entry into his employment agreement with the Company
On September 14, 2023, Brian Chen resigned as Chief Science Officer of the Company, pursuant to a resignation letter, effective immediately.
On September 14, 2023, the Company terminated the employment of Michael Will as General Counsel of the Company, effective as of such date, due to the Company’s current financial constraints and the need to reduce its staff.
the board of directors (the “Board”) of the Company (i) elected Mark White to the Board to serve as a director of the Company, effective immediately
Martin Ward to serve as Interim Chief Financial Officer of the Company, effective as of Mr. Ward’s entry into his employment agreement with the Company
Max materiality 0.85 · Median 0.57 · Most common event other_material